Deprescribing interventions safely and effectively optimize medication use in older people. However, questions remain about which components of interventions are key to effectively reduce inappropriate medication use. This systematic review examines the behaviour change techniques (BCTs) of deprescribing interventions and summarizes intervention effectiveness on medication use and inappropriate prescribing.
Introduction
Older people (aged ≥65 years) are more vulnerable to medication-related harm and inappropriate prescribing than younger chronically medicated people [1, 2] . Agerelated physiological changes contribute to iatrogenic vulnerability in older people, but it is equally a consequence of their multimorbidity and frequent use of multiple medications [1, [3] [4] [5] [6] [7] . Vulnerability, polypharmacy and multimorbidity represent complex challenges in the care of older people and often exclude them from clinical trials [6, [8] [9] [10] . Therefore, some prescriptions in multimorbid older people are without clear-cut evidence to support them and inappropriate prescribing is highly prevalent [11] [12] [13] . Excessive inappropriate prescribing in older people has turned the focus of current research towards deprescribingthe systematic process of identifying and discontinuing drugs in patients for which existing and potential harms outweigh the benefits [14] . Making informed decisions to deprescribe with the goal of reducing inappropriate prescribing and improving patient outcome is hampered by a lack of evidence of withdrawal effects in older people and is further challenged by prescriber-and patient-related factors [15, 16] .
Research has demonstrated safety and effectiveness of deprescribing in older people (aged ≥65 years) [17] whilst reluctance of prescribers to deprescribe a medication commenced by another prescriber is described as well [18] . Although evidence suggests that pharmacist involvement and patient-centred interventions are effective, the best ways to engage and support prescribers in deprescribing remain unclear [16, [19] [20] [21] [22] [23] . Previous reviews examining the effects of deprescribing interventions on clinical outcomes call for a better understanding of successful implementation of deprescribing [6, [17] [18] [19] .
Within the clinical context of patient care, there is a need to ensure that behaviour change is a part of any intervention design in order to maximize the chance that prescribers are enacting on recommendations [24, 25] . Recent advances in behavioural science provide insight into the components of complex interventions aiming at behaviour change. The Behaviour Change Techniques (BCTs) taxonomy version 1 (BCTTv1) [26] is designed to assist in the identification of BCTs of interventions. A BCT is defined as 'an observable, replicable, and irreducible component of an intervention designed to alter or redirect causal processes that regulate behaviour' [27] . A clear description of BCTs will clarify the essential content of these complex interventions in a consistent way to assist in future replication of effective interventions [28] . The application of the BCT taxonomy to deprescribing is novel. This review was designed to complement previous reviews [6, 17, 19] on deprescribing by offering a broader analysis of behaviour change techniques in deprescribing interventions.
The aims of this review are (i) to identify behaviour change techniques used more frequently in interventions effective in reducing number of drugs and inappropriate prescribing, (ii) to describe other characteristics of deprescribing interventions and (iii) to determine intervention effectiveness on drug use, prescribing appropriateness and Medication Appropriateness Index (MAI) score in meta-analyses.
Methods
A systematic search of the primary, secondary and grey literature to identify randomized controlled trials (RCTs) on deprescribing was undertaken on December 14, 2016. This systematic review was reported according to the PRISMA guidelines for systematic reviews and metaanalyses [29] , and was registered in Prospero (record no. CRD42016037730).
Search strategy
The search strategy was designed in conjunction with an experienced medical librarian (JM) who was trained in systematic review methodology. A combination of text words and subject headings (such as MeSH terms) related to the intervention was used, without restricting publication date or language (Table S1 ).
The 
Study selection
One reviewer (C.H.) screened titles of all retrieved citations. Two reviewers (C.H. and S.C.) independently screened abstracts and full-texts for eligibility according to protocoldefined inclusion and exclusion criteria. Any disagreements between reviewers were resolved by consensus and both reviewers agreed on the final inclusion of studies.
Inclusion and exclusion criteria
Inclusion was restricted to randomized controlled study design, including randomized controlled trials (RCTs) and cluster RCTs. The control group could involve either active interventions or inactivity, e.g. sham or no intervention. This study design was chosen to allow for between-study comparison of intervention effectiveness in meta-analyses. Studies were included if they reported on interventions encouraging the deprescribing of existing drugs or the reduction of existing inappropriate prescribing. Only those interventions involving older patients (aged ≥65 years) or a healthcare professional with prescribing, dispensing or administration authority were included. No restrictions were applied to language, clinical setting of the intervention, sample size, blinding procedures or other design characteristics. We excluded interventions specifically focusing on the clinical effects of drug withdrawal processes, e.g. opioid withdrawal effects.
Risk of bias assessment
Risk of bias was assessed separately by two reviewers (C.H. and A.R.) using the Cochrane Collaboration Tool for randomized controlled studies [30] with a descriptive purpose of summarizing the quality of the studies that met inclusion criteria. Studies were not excluded from data analysis because of methodological flaws if they otherwise met inclusion criteria. Incomplete outcome data was in general rated as high risk of bias if the loss of patients to follow-up was 20% or higher and rated as low risk of bias if the loss was 10% or less. Imbalance in the numbers lost to follow-up between intervention and control groups was also considered to introduce bias. The risk of bias assessment is described in detail in Table S2 .
Data extraction strategy
Data were collected using a pre-agreed data extraction form (see Table S3 ). Two reviewers (C.H. and L.S.) independently pilot tested the form on two randomly chosen studies both included in the review. Thereafter data extraction on all studies was completed independently by L.S. and C.H. Disagreements on study inclusion/exclusion were resolved by discussion leading to consensus; where consensus could not be achieved, the study was excluded. Primary outcomes were: (i) number of total and inappropriate prescriptions and/or drugs as defined in the individual studies according to prescribing appropriateness criteria, e.g. STOPP criteria, Beers' criteria and local or national prescribing guidelines; (ii) proportion of participants with a reduction in number of total and inappropriate prescriptions and/or drugs; and (iii) implementation of recommendations. Secondary outcome was change in MAI score.
Behaviour change techniques coding
Coding of BCTs was performed independently by two reviewers (C.H. for all interventions and C.J.A., S.T. and L.S. for a subset of interventions each) by identifying BCTs for each intervention using the BCTTv1 [26] . C.H. had completed online training in BCTTv1. A coding manual and instructions made by C.H. were given to the other reviewers and, exercises from the online training were made available to them. Any questions about the coding were solved by discussion and consensus between the reviewers. The target behaviour was the decision making to discontinue a drug or an inappropriate prescription. Findings were tabulated across studies by computing frequencies. The information was used to determine the BCTs used more frequently in studies that reported effectiveness of interventions to reduce number of drugs and/or improve prescribing appropriateness.
Statistical analysis
We calculated odds ratios (OR) with standard deviations (SD) for each of the reported outcomes and used RevMan v5.3 to statistically combine the outcome data [31] . Continuous outcomes were expressed as difference in means between groups with a 95% confidence interval (95% CI). The level of between-study heterogeneity was evaluated by calculation of the I 2 and Chi-squared statistics. Where possible, stratified random effects meta-analyses was used to identify factors affecting intervention effectiveness. Subgroup analyses were performed by risk of bias assessment, intervention setting and intervention target. If the level of reporting did not allow for inclusion of a study in one or more meta-analyses, additional information was sought from the study authors. If the information was not made available, the study was excluded from the meta-analysis.
Results

Literature search and review process
The database search identified 1444 records, and grey literature yielded 117 records. After removal of duplicates and title screening, 178 abstracts were screened for eligibility and 58 of these met the inclusion criteria. Assessment of full texts resulted in 25 studies included in this review . Study selection and reasons for exclusion are illustrated in Figure 1 .
Study characteristics
Included studies were RCTs (n = 22) [32-41, 43-45, 47, 49-56] and cluster RCTs (n = 3) [42, 46, 48] with a follow-up period from 6 weeks [45] to 13 months [42] . A total of 20 812 patients were enrolled in the studies ranging from 95 [41] to 1188 per study [55] . Detailed study characteristics are provided in Table 1 . Three studies aimed primarily to reduce the number of drugs taken by patients [41, 44, 46] . Other objectives included reduced prevalence of inappropriate medications [32, 33, 38, 39, 42, 49] , improved prescribing appropriateness [34-36, 47, 50-55] , or better patient health outcomes and medicines management [35, 40, 48, 56] . Ten out of the 25 studies included in this review showed evidence to support intervention effectiveness [34, 35, 37, 40, 41, 45, 46, 50, 53, 56] . Most of the studies reporting intervention effectiveness of the key outcomes of this review delivered recommendations or feedback to the prescriber orally, often face-to-face, and many of them followed up on the recommendations/ feedback given. Recommendations and feedback were given immediately after identification of a problem or at the time of prescribing using an on-demand service. For studies reporting no intervention effectiveness on the key outcomes, some delivered recommendations using written communication and many of the interventions did not follow up on the recommendations with the prescriber. None of the included studies reported the use of explicit theories of behaviour change as part of the interventions and no study reported the use of a systematic and theoretical approach, such as the UK Medical Research Council's complex intervention framework [57] , in the intervention design. Reported educational interventions were based on the principles of constructive learning theory in one study [39] and social constructivist learning and self-efficacy theory in another study [46] .
Risk of bias
Risk of bias assessment is illustrated in Figure 2 . Risk of bias not pertaining to any of the defined categories were categorized as 'others' and these are described in Table S2 .
Behaviour change techniques
All but one study [48] reported the behaviour change components underpinning the intervention. The BCT coding is 
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presented in Table S4 . Based on the reported results, 10 of the 25 studies showed an effect on the key outcomes (i) or (ii) of this review when comparing the intervention group to the control group [34, 35, 37, 40, 41, 45, 46, 50, 53, 56] . No direct pattern was seen between the number of individual BCTs used and reported intervention effectiveness. The median number of BCTs used were similar for studies reporting effective and non-effective interventions (6 BCTs, IQR 3-8 and 5 BCTs, IQR 4-7, respectively). BCT clusters coded more frequently in studies reporting effectiveness [34, 35, 37, 40, 41, 45, 46, 50, 53, 56] compared to studies reporting no effectiveness were: goals and planning; social support; shaping knowledge; natural consequences; comparison of behaviour; comparison of outcomes; regulation; antecedents; and identity (see Figure 3 ).
Intervention effectiveness (a) Drug use
Overall, the mean number of drugs post-intervention was significantly lower among intervention participants compared to the control participants in the presence of moderate between-study heterogeneity (mean difference À0.96, 95% Figure S1 ). Regarding the difference in change in the number of drugs taken per patient, deprescribing interventions lowered the number (À0.74, 95% CI À1.26, À0.22), but effects varied greatly across studies (I 2 = 92%, P < 0.001) (Figure 4 ). Stratified analyses by: (i) whether the intervention was patient-centred or targeting solely healthcare professionals ( Figure S2 ), (ii) intervention setting ( Figure 4 ) and (iii) study quality ( Figure S3 ) showed no effect of these factors on summary estimates. In addition, the unexplained variation within subgroups remained large. Figure S4 ). The proportion of participants with at least one inappropriate drug, as defined in the individual studies, were reduced when a deprescribing intervention was applied, but confidence intervals were wide, and a high level of heterogeneity was present ( Figure 5 ).
(c) Implementation of recommendations
Only four studies reported implementation rates of recommendations to discontinue a medication or change a medication [36, 38, 43, 49] . Action was taken in 55.1% of recommendations given by a pharmacist compared to only 19.8% of the nurse recommendations as part of usual pharmaceutical care [36] . In the study by Vinks et al. [43] , 27.7% of pharmacists' recommendations were implemented, and action was taken in 56% of drug-related problems identified by a pharmacist in Milos et al. [38] . A lower recommendation implementation rate of 15.4% was shown in Fick et al. [49] . This result was based on self-reported action taken by the physicians; only 71% of physicians reported this, which may explain the lower frequency of action observed.
(d) MAI score Seven studies reported changes in MAI scores for participants pre-and post-interventions [34, 36, 47, 48, 51, 53, 54] . Across studies, deprescribing interventions demonstrated a significant effect on reducing the MAI score comparing intervention and control groups post-intervention (À5.04, 95% CI À7.40, À2.68, heterogeneity I 2 = 88% and P < 0.0001, Figure S5 ).
Discussion
Effectiveness of deprescribing interventions is determined by a combination of factors. Consistent with the findings of recent reviews [6, 17] , our meta-analysis showed that deprescribing interventions are effective in reducing the number of drugs and inappropriate prescribing (reduced MAI scores) in older people, although the evidence is heterogeneous.
Based on the findings of the BCT coding exercise, effective deprescribing interventions included: (i) a goal and an action plan to solve prescribing problems, (ii) monitoring of behaviour, (iii) social support and the use of a credible source, and (iv) clear instructions and guidance on implementation to the prescriber and information about health consequences of doing/not doing the behaviour. Support from colleagues and information about potential risks and benefits to the patients in the presence/absence of a behaviour change may also be effective techniques of deprescribing.
Differences in the delivery of prescribing recommendations were seen in the studies reporting intervention effectiveness compared to studies reporting no effect on key outcomes of this review. Studies reporting effectiveness [34, 35, 37, 40, 41, 45, 46, 50, 53, 56] used oral and faceto-face communication to discuss and implement deprescribing recommendations consistent with the principles of educational outreach to inform clinical decision making as described by Soumerai and Avorn [58] . Investigation of the delivery of recommendations to deprescribe may provide useful information on the delivery of a successful deprescribing intervention in addition to the use of BCTs.
Figure 4
Mean difference in the change in number of drugs comparing experimental (intervention) group and control group. Subgroup analysis on intervention setting (outpatient setting versus hospital setting) Pharmacist recommendations to reduce drug intake and inappropriate prescribing were frequently enacted on in some studies [36, 38] , consistent with previous literature reporting benefits of pharmacist-led interventions to optimize medication use in older people [21, 59] . Other studies [43, 49] reported a lower acceptance rate of pharmacist recommendations, between 15% and 28% of recommendations enacted on. Recent research has demonstrated a high level of agreement between prescribers and pharmacists in the assessment of potential target medications for deprescribing [60, 61] . In contrast, other research studies indicate that acceptance rates for recommendations made by pharmacists are lower than those made by their physician colleagues [62] . The lower uptake of pharmacist recommendations despite a high level of agreement about deprescribing is noteworthy. It may indicate that challenges to deprescribing are in fact dependent on the particular ways deprescribing interventions are delivered, particularly when there is a question of behaviour change. Based on the findings of this review, we suggest that future research should investigate the behaviours associated with the acceptance and rejection of deprescribing recommendations to gain a better understanding of a successful delivery of deprescribing interventions. This is the first review to identify BCTs in deprescribing interventions necessary to achieve a change in behaviours towards deprescribing. Our findings complement previous reviews on deprescribing [17, 19] by offering a broader analysis of BCTs that are effective for deprescribing.
Limitations and strengths
The review findings are based on a comprehensive search of the literature. The novel aspect of this review is in the use of a validated taxonomy to describe intervention content that facilitates behaviour change. Limitations of this review reside mostly in the limited data available. RCTs to date are of a relatively small size (often ≤100 participants) and usually with short follow-up periods. Other limitations relate to the high-risk blinding procedures; these were needed because the interventions in question required blinding of the personnel whose behaviour was targeted, and this was logistically difficult. Absence of blinding procedures for outcome assessors were not considered to introduce important bias because the study outcomes, e.g. number of drugs taken, was not a particularly subjective measure. Random sequence generation and allocation concealment were considered high importance biases in this review because participant characteristics such as multimorbidity, age and polypharmacy could have an impact on the number of drugs taken and risk of inappropriate prescribing [1, [5] [6] [7] [8] .
The meta-analysis was reliant on published or reported data and, while some reported outcomes were adjusted for baseline patient characteristics, others were not, which makes the direct comparison of intervention effect on specific outcomes open to question. Similarly, and as described in a previous review [27] , the BCT coding was limited to the intervention descriptions reported in the studies. Limited reporting on interventions used to encourage deprescribing could have resulted in BCTs being undercoded 
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and others overcoded due to assumptions made about the strategies used based on the information available. For example, we assumed that the reporting of prescribing recommendations given to the prescriber would involve BCT codes: instructions on how to perform a behaviour and feedback on behaviour. Prescribing recommendations were a commonly used intervention in the studies and this may have resulted in these two BCTs being overcoded. One study was also excluded from the BCT coding due to lack of information which could have potentially impacted the true findings of this review. Furthermore, we were unable to code BCTs in the control groups due to limited reporting of the control conditions. The control conditions such as usual care in hospital settings or in outpatient settings could include BCTs with potential implications on the interpretation of the review findings. Reporting of future behaviour change interventions and control conditions will benefit from the use of comprehensive checklists, such as the TIDieR [63] , and give reviewers the ability to adequately code BCTs and extensively appraise the reporting quality of such interventions.
This will improve the identification of relationships between BCTs used and intervention effectiveness.
The main limitation of our pooled estimates is the presence of typically large between-study variation and, for some of the analyses, the wide confidence intervals including trivial effects. Some may argue that a metaanalysis should not be done in the presence of important heterogeneity. Meta-analytical methods, however, allow for the exploration of sources of heterogeneity and we fully acknowledge that the magnitude of the summary estimates should be interpreted with care. To minimize the level of heterogeneity due to different study designs, we also decided to limit the inclusion criteria to randomized controlled studies and cluster randomized controlled studies only. Although the direction of effect was favouring deprescribing, the magnitude of effect was very variable. This inconsistency, together with the imprecision and risk of bias issues lower our confidence in the estimates of effect so that the magnitude of effect is very low.
Conclusion
Deprescribing interventions are effective in reducing the number of drugs taken by patients and improving prescribing inappropriateness. Their success may be explained by a combination of BCTs spanning a range of different intervention functions, although we could not empirically show this. The use of BCTs and delivery of such behaviour change interventions should be considered of importance to facilitate successful implementation of deprescribing. This review contributes to the existing evidence by critically analysing the content of deprescribing interventions in terms of behaviour change, clearly demonstrating that the current evidence base is too small to derive strong conclusions on determinants of success.
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